Recent Headlines
Huntington Study Group® Holds 30th Annual Meeting
The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023 - Huntington Study Group
Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable
The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group
Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group
PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars
PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies. Applications are due July 10, 2023. - June 06, 2023 - PharmStars
GenInvo Part of PHUSE US Connect & Informa Connect Clinical Data Disclosure, Transparency & Plain Language Summaries Event - 2023
GENINVO was a part of 2 recent global events for the life science industry. The first was "PHUSE US Connect 2023" which was held in Renaissance Orlando at SeaWorld Florida on 5th – 8th March 2023 and the second event, Informa Connect Clinical Data Disclosure, Transparency &... - June 05, 2023 - GenInvo, Inc.
Huntington Study Group Announces Call for Abstracts for 30th Annual Meeting
The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for those impacted by Huntington’s disease, together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease... - June 01, 2023 - Huntington Study Group
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023 - Huntington Study Group
PharmStars Announces Spring 2023 Startup Showcase Event Underway
PharmStars, the pharma-focused accelerator for digital health startups, announces that its fourth Showcase Event begins May 16, 2023. The Showcase is the culmination of the Spring 2023 10-week accelerator program. At the Showcase, each startup in the fourth cohort makes a formal presentation to and meets individually with PharmStars’ pharma members. The theme of the Spring 2023 program is digital innovations in women’s health or health equity. - May 16, 2023 - PharmStars
Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces an important milestone in the novel observational study Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™). The last participant completed the last visit, marking... - May 16, 2023 - Huntington Study Group
HSG and HD-CAB Collaborate to Provide Global Patient Advisory Board
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), recently collaborated with Huntington’s Disease – Community Advisory Board (HD-CAB) to provide a... - March 30, 2023 - Huntington Study Group
HSG Announces 30th Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently announced that their 2023 Annual Meeting will be held November 2-4, 2023 at the Sheraton Grand at Wild Horse Pass in Chandler, AZ, a... - March 21, 2023 - Huntington Study Group
GENINVO Launches Its Latest Offering – Datalution
GenInvo, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Datalution. GenInvo has recognized various challenges the pharmaceutical industry faces, especially in generating data for clinical trials. The need of clinical data to... - March 11, 2023 - GenInvo, Inc.
Huntington Study Group Names First Chief Innovation Officer
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, today announced Brett Kinsler has been named to the newly created position of Chief Innovation Officer (CINO). - January 10, 2023 - Huntington Study Group
PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event--held in Boston in early November--that brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - December 08, 2022 - PharmStars
PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Spring 2023 cohort with the theme “Digital Innovations in Women’s Health and Health Equity.” Startups with digital innovations that promote more equitable, inclusive healthcare for underserved population or focused on women’s health (e.g., breast, ovarian, and cervical cancer; gynecological conditions; osteoporosis; menopausal, hormonal, and reproductive conditions) are welcome to apply. - December 05, 2022 - PharmStars
Clinical Research Organization, Huntington Study Group “Firsts” Continue
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022 - Huntington Study Group
Huntington Study Group Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022 - Huntington Study Group
PharmStars Announces Fall 2022 Startup Showcase Event
PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group
Kantify and Mcule Harness the Power of Data to Accelerate Drug Discovery
Kantify, using its AI technology for drug discovery and Mcule, with its compound sourcing platform, are collaborating to leverage data for better hit prediction. - October 17, 2022 - Mcule
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group
Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Based Organizations at Asia’s Premier Biotechnology Partnering Event
Tasly Pharmaceuticals will exhibit at BioJapan 2022, October 12-14 at PACIFICO Yokohama - October 05, 2022 - Tasly Pharmaceuticals, Inc.
Appointments Made to the Sterile Compounding Expert Panel Announced by Pharmacy Stars
The Sterile Compounding Expert Panel (SCXP) was established by Pharmacy Stars on July 7, 2022. Pharmacy Stars executive leadership has appointed key members to serve on SCXP’s panel. They have joined in support of the organization’s mission to strengthen sterile compounding practices in... - September 12, 2022 - Pharmacy Stars, LLC
GENINVO Service Offering Custom Application Development
GENINVO is a leading provider of high-quality, innovative life science tools. GENINVO understand the business challenges of enterprises big and small. Whether you need short-term, focused design support or turnkey product development, GENINVO has the right tools to meet your needs with the help of... - September 07, 2022 - GenInvo, Inc.
PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars
Pharmacy Stars’ New Sterile Compounding Quality Peer Network Aims to Fill the Role Once Held by the Now Discontinued CriticalPoint Peer Network
Pharmacy Stars to launch the Sterile Compounding Quality Peer Network with the goal of filling the vacated role of CriticalPoint’s Peer Network, an online forum designed to support 503A entities, their regulators, and their certifiers. The CriticalPoint Peer Network has been discontinued as of June 30, 2022, according to the CriticalPoint website. - July 11, 2022 - Pharmacy Stars, LLC
River Valley Relief Names Ryan Kenaga President
River Valley Relief (RVR), a family-owned medical cannabis cultivator located in Fort Smith, Arkansas makes some organizational changes and names new President. - July 08, 2022 - River Valley Relief
PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars
GENINVO Launches Its Latest Offering - Innovation as a Service
GENINVO, a leading provider of life science product and business solutions announced the launch of its new, on-demand service: Innovation as a Service. GENINVO has recognized various challenges the pharmaceutical industry faces, especially in the wake of the pandemic. The need to expedite clinical... - June 12, 2022 - GenInvo, Inc.
PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort
PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars
Pharmaceutical Compliance Partners Selects Luke Forman, University of Notre Dame, for Summer Internship Program
Pharmaceutical Compliance Partners selected Luke Forman, a Science-Business major at University of Notre Dame, as its first summer intern. This is the inaugural year for Pharmaceutical Compliance Partners’ internship program, allowing students to learn about drug development, pharmaceutical compliance, and business operations of life sciences firms. - May 25, 2022 - Pharmaceutical Compliance Partners
River Valley Relief Launches Relief by RVR Line of Marijuana Concentrates
Arkansas has always been a state known for finding diamonds; just maybe not the kind that are coming out of Fort Smith recently. River Valley Relief Cultivation (“RVR”) has been hard at work producing live diamonds, among other live resin extracts, that were released to many Arkansas... - April 15, 2022 - River Valley Relief
Decarbitation Inc. Product Launch: New Cannabis Crude Oil Decarboxylation Technology Using Controlled Cavitation
DecarbitationTM will be launching its website as well brand new 2 and 25 gallon systems for the decarboxylation of cannabis on February 2, 2022. - February 01, 2022 - Decarbitation Inc.
PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars
PharmStars Announces 2021 Accelerator Graduates
12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars
GENINVO Launches Centre of Excellence for Data Science and Analytics to Help Clients Unlock Insights Using Data Science
GENINVO, a leading provider of life sciences product and business solutions organization, announced the launch of a Centre of Excellence for Data Science and Analytics (DSA CoE). The DSA is a resolute team of experts comprising of life science and technology domains. Data Science and Analytics CoE... - November 18, 2021 - GenInvo, Inc.
PharmStars Announces Showcase Event for Inaugural Class
PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars
South-Tek Systems Appoints Jens Bolleyer as CEO
South-Tek Systems announces Jens Bolleyer was appointed as the company’s CEO effective August 30, 2021. An experienced business leader, Mr. Bolleyer steps into the CEO role at South-Tek with significant experience in manufacturing businesses serving commercial & industrial plumbing and... - November 16, 2021 - South Tek Systems
PharmStars Welcomes Sumitovant Biopharma as Its Newest Member
PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars
Omni-HC Selected to Participate in “Audience Amplification” Workshop at Prestigious Global Medical Affairs Meeting
Omni Healthcare Communications has been selected by the Medical Affairs Professional Society to convene a workshop on scientific communication amplification at the MAPS 2022 Global Annual Meeting. - October 02, 2021 - Sunny Ayr Holdings
AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.
AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure
Synformulas Presents the Scientifically Researched Potential of Its Products for the First Time at Vitafoods Europe
Common diseases such as gastrointestinal conditions and allergies are the focus of the company’s research and product development; More value is being added for further licensing and distribution partners through strong scientific research results; SYNformulas is seeking for additional distribution partners to expand its internationalization activities with its patented active complexes. - September 13, 2021 - SYNformulas
Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities
Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings
GENINVO Launches Updated New Website
After months of hard work and dedication, GENINVO is pleased to announce the new and updated website launch. The primary goal of the redesign process was to create a user-focused design, add improved functionality, and provide easy access to information about GENINVO’s products and services. - June 14, 2021 - GenInvo, Inc.
eCTD Solutions Appoints New CEO and Changes Name to Highlight Expanded Capability
Sunny Ayr Holdings, a group of healthcare product solutions companies, is pleased to announce the change of the name of eCTD Solutions Ltd. to Omni Early Development Services and the appointment of Mark Marino, MD as Partner and Chief Executive Officer of the early product development solutions provider. - May 19, 2021 - Sunny Ayr Holdings
G1 Care Pharma Selected Authorized Distributer of Vaidyaratnam and Himalaya Products
G1 Care Pharma is a rising hybrid digital pharma retail chain company based in Kota, Rajasthan, India with the aim to provide generic medicines at low costs. G1 Care Pharma is also and authorized distributer of Vaidyaratnam and Himalaya Wellness Ayurvedic products in India. G1 Care Pharma is a... - November 07, 2020 - G1 Care Pharma